Jim Cramer Says Cardinal Health Is "the Stock That Is Made for This Moment"
Jim Cramer highlighted Cardinal Health (CAH) as "the stock that is made for this moment," noting its strong performance with shares climbing 34% year-to-date. The company recently beat earnings and revenue estimates, raised guidance, and renewed a critical contract with CVS through 2032. While the stock's valuation at 22x forward earnings suggests much of the rally is priced in, its defensive nature and consistent profitability make it a durable compounder for long-term investors.
CVS Pharmacy® names Grand Prize winners of first Home Team Heroes youth soccer contest
CVS Pharmacy has announced Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, California, as the Grand Prize winners of its inaugural Home Team Heroes youth soccer contest. Each winner's nonprofit soccer organization will receive a $25,000 grant, and the girls will be featured on limited-edition Well Market snack packaging slated to arrive on select CVS Pharmacy shelves in 2027. This initiative serves as a brand marketing and community program for CVS Health.
Bull of the Day: Humana (HUM)
Humana (HUM) has transformed from a struggling managed care company to a top performer within a year, driven by a successful turnaround in its Medicare Advantage Star Ratings. The company exceeded its quality goals and posted strong third-quarter results, prompting analysts to raise earnings estimates for both the current and next year. Humana's stock has gained 48% year-to-date and is seen as a compelling investment due to strong fundamentals and a powerful technical uptrend.
Why CVS Health (CVS) Cracked the Best Affordable Blue Chip Stocks List
CVS Health Corporation (NYSE:CVS) was ranked 9th on a list of the 10 Best Affordable Blue Chip Stocks to Buy Now, primarily due to its forward P/E of 10.58 and an analyst upside of 24.36%. The company's investment case is centered on improving insurance profitability and maintaining strong pharmacy and healthcare services operations, evidenced by a significant recovery in its Health Care Benefits segment's adjusted operating income. Despite ongoing elevated healthcare costs, CVS raised its full-year adjusted earnings guidance to at least $8.20 per share, supported by better underwriting performance.
VA raised Oracle’s contract cap to $27B. Auditors still can’t verify the cost of the rollout.
The Department of Veterans Affairs increased Oracle's electronic health record contract ceiling by $17 billion to $27 billion, with plans to accelerate system deployment in 2027. Despite this, federal auditors from the Government Accountability Office still lack the necessary documentation to verify the total project cost, estimated at $56.5 billion, or confirm if the 2031 completion date is feasible. Concerns persist regarding inflation assumptions, undefined work scope, and the significant increase in contract value compared to similar large-scale health system implementations.
Modular Medical Secures Coverage Agreements with All Three of the Nation's Largest PBMs for Pivot Insulin Delivery System
Modular Medical, Inc. announced agreements with the remaining two of the nation's three largest pharmacy benefit managers (PBMs) for its Pivot™ tubeless patch pump, establishing broad coverage across commercial, Medicare, and Medicaid plans. These agreements, which cover over 182 million lives and approximately 80% of U.S. prescription claims, are a significant milestone for the company's full commercial launch and aim to increase patient access and affordability for insulin pump therapy. The company believes this will help reduce traditional coverage barriers and support the transition from multiple daily injections to advanced pump therapy.
Aetna For You & Baby: maternal and infant care by 2032
Aetna has launched "Aetna For You & Baby," a five-year initiative aiming to connect 90% of its expecting mothers and their babies to essential, end-to-end care by 2032. This initiative focuses on prenatal and postpartum physical health, maternal mental health, and ensuring infants receive six or more well-child visits in their first 15 months, addressing preventable pregnancy-related deaths and improving early childhood development outcomes.
Gix Internet Launches Carelee, a Physical AI Platform for
Gix Internet Ltd., through its subsidiary deliverz.ai, has launched Carelee, an AI-assisted workforce orchestration platform for hospital-at-home programs. This platform aims to streamline caregiver dispatch, visit assignment, and route optimization in the growing $169 billion U.S. home health care sector. Carelee offers both marketplace and automatic assignment modes, providing real-time visibility and leveraging Gix's Physical AI strategy to extend intelligent orchestration beyond hospital logistics to in-home care.
Major grocery store chain wants you to pay less for food: How it plans to make that happen
Kroger, one of America's largest grocery chains, is implementing a new pricing strategy to offer lower everyday prices on thousands of items. The company plans to shift funds from complex promotions into permanent price reductions, investing $5 billion in customer value by 2029. This initiative aims to simplify shopping and ensure more products consistently carry lower prices.
Major grocery store chain wants you to pay less for food: How it plans to make that happen
Kroger is implementing a new pricing strategy to offer lower everyday prices on thousands of items, rather than relying on complex temporary promotions. The grocery chain plans to invest $5 billion in customer value by 2029, funding this shift by reallocating money from promotions and achieving $4 billion in annualized cost savings through operational efficiencies. This initiative aims to simplify shopping for customers and ensure more products consistently carry lower prices.
Target Corporation (TGT) Stock Forecasts
This article provides an analyst report for Target Corporation (TGT) from Morningstar, dated November 18, 2026. It discusses Target's business, which includes nearly 2,000 stores and over $104 billion in fiscal 2025 sales, noting that category resets drive traffic but apparel and home departments temper the mix. The report also suggests that shares are pricey.
CVS HEALTH Corp Initial Statement of Beneficial Ownership
Teresa A. Heitsenrether, a director at CVS Health Corp (CVS), filed an Initial Statement of Beneficial Ownership of Securities (Form 3) with the SEC on November 18, 2026. This filing indicates that Heitsenrether beneficially owns no securities directly or indirectly at the time of the statement. The document serves to report her initial status as a reporting person with the company.
Healthcare stocks (UnitedHealth, Humana, CVS, Cigna) fall on new Medicare rules
Shares of major healthcare insurers like UnitedHealth, Humana, CVS Health, and Cigna Group dropped following new Medicare rules proposed by the Centers for Medicare & Medicaid Services (CMS). These stricter oversight measures, particularly expanded Medicare Advantage audits and retrospective payment recoveries, raised concerns about future profitability, with CMS estimating potential federal budget savings of nearly $90 billion. While investment banks maintain generally positive price targets, the selloff highlights investor apprehension regarding regulatory challenges and their impact on earnings.
All Michigan CVS Pharmacy® locations now authorized to accept WIC for infant formula
All 179 CVS Pharmacy locations in Michigan are now authorized to accept the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) for infant formula purchases. This expansion makes Michigan the second state, after Rhode Island, where all CVS Pharmacy stores are approved for the program, enhancing access to essential infant nutrition for families relying on WIC benefits.
Humana Drops 8.5% Intraday: What the Selloff Looks Like
Humana (HUM) experienced an 8.5% intraday drop, falling from its $441.37 open to stabilize in the low $400s, an unusually sharp move for a large managed-care insurer. Competitor Clover Health (CLOV) also fell by 7.2%, suggesting an industry-wide event rather than company-specific news. Investors are closely watching whether the $401 intraday low will hold as a support level.
UnitedHealth, Humana and Elevance fall sharply after Medicare audit proposal
UnitedHealth, Humana, and Elevance Health experienced significant stock declines following a CMS proposal to extend Medicare Advantage audit recoveries back to 2018. The proposal, which could amount to roughly $9 billion per payment year, led to a combined paper loss of about $43 billion for the three companies by early afternoon on November 18, 2026. Analysts expect potential legal challenges to the rule, with Oppenheimer suggesting recoveries may be concentrated later and priced into future bids.
UnitedHealth and Humana fall after CMS proposes a $90 billion anti-fraud rule
Shares of UnitedHealth Group, Humana, CVS Health, and Cigna fell after the Centers for Medicare & Medicaid Services (CMS) proposed a new Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) rule. This rule aims to recover an estimated $90 billion over 10 years through tougher audits of Medicare Advantage insurers, extrapolating audit findings and requiring reporting of suspected fraud. The proposal, scheduled for publication on November 19, 2026, is open for comments until January 19, 2027, and follows a previous court setback for similar provisions.
Unitedhealthcare Partners With Independent Pharmacies for Telehealth and Testing
UnitedHealthcare, a unit of UnitedHealth Group Inc. (NYSE:UNH), has partnered with CPESN USA to launch a new care delivery model leveraging independent pharmacies for telehealth and testing services. This initiative aims to expand access to high-quality healthcare, especially in rural and underserved communities, by utilizing pharmacists as local access points. The program connects members with virtual care providers, offers point-of-care testing, and provides personalized health support to close care gaps and improve coordination.
CVS Health Raised Its 2026 Outlook 3 Times, but Not Its Dividend
CVS Health has maintained its dividend at $0.665 per share for 12 consecutive quarters despite raising its 2026 guidance three times, now expecting at least $8.20 adjusted EPS and $15.5 billion in operating cash flow. The company prioritizes share buybacks and a planned split into two public companies by the first half of 2028, with debt reduction achieved ahead of schedule. While financially capable of a dividend increase, strategic priorities currently take precedence, though Aetna's improved medical benefit ratio strengthens the long-term case.
Capital One Bank Review – Free Cash Deposits at Stores and In-Person Help
This article reviews Capital One Bank, highlighting its suitability for savers who frequently deposit cash or require occasional in-person assistance. It emphasizes features like free cash deposits at thousands of retail stores, 70,000+ fee-free ATMs, and the presence of branches and Cafés. The review also details the bank's 360 checking, savings, and CD products, including APY rates and terms, while comparing its savings rate to competitors.
Five9 Announces Winners of the 2026 New Era of CX Awards
Five9 (FIVN) announced the winners of its 2026 New Era of CX Awards, recognizing customers who achieved significant improvements in customer experience using its platform. The awards highlighted measurable gains such as a 77% drop in average speed to answer at IAA and a 75% cut in average call time at Doctor Care Anywhere, along with over 250,000 lifeline interactions handled by AI at TruConnect. While the release did not include financial figures for Five9, it showcased successful platform adoption by large organizations like CVS Health and Wells Fargo.
Vaxcyte at jefferies global healthcare conference: adult vaccine path sharpens
Vaxcyte provided updates on its pneumococcal vaccine franchise at the Jefferies Global Healthcare Conference, highlighting positive Phase III adult study data for VAX-31 which met all endpoints and demonstrated non-inferiority to existing vaccines while offering broader coverage. The company aims for a biologics license application filing in the first half of 2028 and anticipates Phase II infant program data in the first half of 2027. Vaxcyte sees a substantial commercial opportunity in the adult market, which is expected to grow significantly, driven by broader serotype coverage.
PACE Organization InnovAge Agrees to Pay $36M to Resolve False Claims Act Allegations
InnovAge Holding Corporation has agreed to pay $36 million to settle allegations that it violated the False Claims Act and state laws. The company is accused of failing to provide comprehensive medical services and timely specialist referrals to its elderly patients enrolled in the PACE program. This settlement highlights the government's commitment to holding PACE organizations accountable for the care of vulnerable seniors.
Novo expands DTC program Novocare to support Wegovy users through holistic health journey
Novo Nordisk has rebranded its direct-to-patient pharmacy, NovoCare, to offer expanded services for Wegovy users, moving beyond just prescriptions to provide holistic health support. The program now includes treatment information, coaching, progress tracking, and partnerships with brands like Whoop and Stitch Fix to aid in lifestyle changes. NovoCare aims to be a comprehensive hub for patients and healthcare professionals, ensuring access to authentic medication and resources for navigating weight loss journeys.
CVS Health Corp Stock (CVS) Moved Down by 3.26% on Nov 17: What Signal Does It Send?
CVS Health Corp's stock (CVS) fell 3.26% on November 17, driven by investor concerns about medical cost trends in its managed care division and ongoing challenges in the retail pharmacy sector. The company's valuation is sensitive to utilization patterns in its Aetna health benefits business, with elevated outpatient procedure volumes and tightened government reimbursement rates impacting margins. Analysts maintain an average price target of $111.25 for CVS, despite the current downward pressure.
Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments
The Centers for Medicare & Medicaid Services (CMS) has proposed significant program integrity reforms aimed at combating fraud, waste, and abuse across federal healthcare programs, potentially saving nearly $90 billion over the next decade. The "Comprehensive Regulations to Uncover Suspicious Healthcare" rule strengthens Medicare Advantage audits, mandates reporting of suspected fraud, and protects seniors from unwanted solicitations. Additionally, it tightens oversight for Medicaid and CHIP and prevents unauthorized enrollments in the Health Insurance Marketplace.
CVS Health Stocks Fall 3.12% as Aetna Faces Tougher Medicare Advantage Audit Rules
CVS Health shares dropped 3.12% after the Department of Health and Human Services proposed new rules to toughen audits of Medicare Advantage plans, including CVS's Aetna unit. The proposed rule would allow CMS to extrapolate risk adjustment audit results across entire contracts, impacting managed care companies. Despite CVS having a diversified business with pharmacy and benefits, investors are awaiting management's exposure estimates regarding the potential impact of these new regulations.
CVS Health Corp. stock underperforms Tuesday when compared to competitors
Shares of CVS Health Corp. (CVS) fell 3.14% on Tuesday, closing at $85.81, amidst a broader market downturn. The S&P 500 Index (SPX) declined 1.03%, and the Dow Jones Industrial Average (DJIA) dropped 1.64%, marking the third consecutive day of losses for CVS.
UnitedHealth Stock Drops 4%: What’s Going On?
UnitedHealth Group (NYSE:UNH) shares dropped after Senator Elizabeth Warren called for breaking up major healthcare conglomerates, including UnitedHealth, citing concerns over their vertical integration and influence on patient care. Concurrently, the Centers for Medicare & Medicaid Services (CMS) proposed new "CRUSH" rules to combat healthcare fraud, waste, and abuse, further impacting the sector. These combined pressures led to a significant decline in UnitedHealth's stock price.
ServiceNow Sees AI Usage Surge as It Raises Annual Contract Value Target to $1.7 Billion
ServiceNow is experiencing a surge in customer adoption of its AI tools, particularly those automating finance, procurement, and HR, leading the company to raise its annual AI contract value target to $1.7 billion from $1 billion. Josh Kahn, SVP and GM of Core Business Workflows, highlighted increased agentic AI consumption, growth in EmployeeWorks customers, and strong demand for the Core Business Suite as key drivers. Despite this progress, back-office AI applications are still less mature than IT service-desk use cases, and ServiceNow is exploring new pricing models and deployment strategies to accelerate adoption beyond traditional IT budgets.
CVS Health shares technical analysis: Downward momentum persists near $83.81 support
CVS Health stock is experiencing persistent downward momentum, trading below key moving averages despite the company receiving seven Stevie Awards for AI-driven healthcare innovations. Technical analysis suggests continued selling pressure with the stock currently at $85.21 and a projected volatility band between $83.81 and $88.26. While long-term sentiment may improve due to technological advancements, the immediate outlook remains weak, with a 75% probability of a rebound within the current range.
e.l.f. Brands Expands Impact Through Glow For Glory Contest with the National Women’s Soccer League (NWSL)
e.l.f. Cosmetics and e.l.f. SKIN are returning as sponsors for the NWSL Championship for the second year, expanding their "Glow For Glory" contest, which saw over 1,200 submissions from young girls. The five finalists will transport the official Championship Match Ball from New York to Washington, D.C., including meet-and-greets with NWSL players and a shopping spree. This initiative reinforces e.l.f.'s commitment to empowering women and girls in sports, supported by research showing a strong link between sports participation and leadership roles.
UnitedHealth's outside review praised how medical policies are written—but did not examine the denials patients actually experience
An outside review commissioned by UnitedHealth Group found that its insurance arm uses a strong, evidence-based process to write medical policies, but the review notably did not examine how these policies are applied to individual patients, including approval or denial of care. This omission is significant for patients and doctors who frequently dispute UnitedHealthcare's denial decisions. While the review praised the company's policy development, outside data from KFF and the HHS inspector general indicate high denial rates and overturn rates on appeal for UnitedHealthcare, suggesting a disconnect between policy quality and patient experience.
Glenview ups stakes in Meta, Teva; cuts CVS, Block in Q3; exits DKS, STM (META:NASDAQ)
Glenview Capital Management increased its holdings in Meta Platforms (META) and Teva Pharmaceutical Industries (TEVA) during the third quarter. Conversely, the fund reduced its stakes in CVS Health (CVS) and Block (SQ) and completely exited positions in Dick's Sporting Goods (DKS) and STMicroelectronics (STM). Glenview also disclosed new or maintained positions in Surgery Partners (SGRY), Marvell Technology (MRVL), and Oracle (ORCL).
Elizabeth Warren Targets CVS, UnitedHealth and Cigna, Says Healthcare Giants ‘Take a Cut at Every Step’ as She Calls for Breaking Up Conglomerates
Senator Elizabeth Warren is advocating for the breakup of major healthcare conglomerates like CVS Health Corp, UnitedHealth Group Inc., and The Cigna Group, arguing they "take a cut at every step" due to their vertical integration. Her "Break Up Big Medicine Act" would prevent health insurers, PBMs, and wholesale drug distributors from owning healthcare providers. Warren's proposal targets the broad influence of these companies across pharmacy, insurance, and patient care, challenging their business structures and acquisitions.
McKesson stock at EUR 1,001.75, down 0.91% premarket
McKesson stock opened premarket trading down 0.91% at EUR 1,001.75, following a close of EUR 1,011.00 on Monday. The company recently raised its fiscal 2027 adjusted EPS outlook to USD 45.60-46.40, up from USD 44.20-45.00, after strong second-quarter results driven by higher-margin oncology and technology businesses. Strategic initiatives include the planned Medical-Surgical separation and a proposed investment in Option Care Health.
Powerfleet Director John Strosahl Awarded 24,306 RSUs on November 16, 2026
Powerfleet Director John Strosahl was awarded 24,306 restricted stock units (RSUs) on November 16, 2026, as disclosed in a Form 4 submitted to the SEC. These RSUs, granted under the company's 2018 Incentive Plan, will fully vest on the earlier of one year from the grant date or the next annual stockholders meeting, contingent on his continued board service. Following this transaction, Mr. Strosahl directly beneficially owns 24,306 common stock shares of Powerfleet, Inc.
American Century and Stowers Institute Reveal 5.5% Stake in Trex Company via Schedule 13G Filing
American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research have disclosed a joint 5.5% beneficial ownership in Trex Company, Inc. common stock as of September 30, 2026, through a Schedule 13G filing. This holding amounts to 5,571,086 shares, with each entity maintaining sole voting and dispositive power over their respective shares. The filing clarifies that these securities were acquired and are held in the ordinary course of business, not for influencing company control.
e.l.f. Brands Expands Impact Through Glow For Glory Contest with the National Women’s Soccer League (NWSL)
e.l.f. Beauty announced its return to the National Women's Soccer League (NWSL) Championship for a second year, reaffirming its commitment to women's sports and youth athletes through the Glow For Glory contest. The company is expanding its partnership to reach over 25,000 girls and women players, with five finalists traveling 250 miles with the official Championship Match Ball. e.l.f.'s research highlights that girls who play sports are more likely to hold leadership roles and aspire to senior positions in the workplace.
Learn Why The Bull Case For Cigna Group Stock Could Change Following Quarterly Earnings
Cigna Group reported mixed Q3 2026 results with higher sales and revenue but lower net income, raising concerns about cost trends and margin pressure. Investors will closely scrutinize commentary from Cigna Group's CFO at the upcoming UBS Global Healthcare Conference for insights into business drivers and strategies to address profitability. The article highlights the tension between strong cash flows from Evernorth and Cigna Healthcare and the ongoing regulatory and cost pressures affecting the company's profitability.
OpenAI Unveils AI Agent That Directly Operates Hospital Systems, Adopted by CVS and Cigna
OpenAI has launched a "ChatGPT for Healthcare" update featuring an AI agent capable of directly interacting with hospital and insurer software to automate administrative tasks like preparing MRI orders and prior-authorization forms. This agent has been adopted by CVS Health and Cigna Healthcare, significantly reducing backlogs and information search times. The update also includes improved clinical search features and expanded plugin support from various healthcare companies, shifting medical AI's focus from diagnostic assistance to administrative automation.
CVS or British American Tobacco: The One Dividend Stock I’d Hold for the Next 10 Years
This article compares CVS Health (CVS) and British American Tobacco (BTI) as long-term dividend investments, focusing on their yields, dividend growth, and payout ratios. While CVS has a lower yield but ample cash flow coverage and a planned split, BAT offers a higher yield with tighter coverage and slower growth, but a stronger balance sheet. The author ultimately recommends British American Tobacco for a 10-year hold due to its higher current yield and consistent, albeit modest, dividend growth.
Nine-month loss narrows 66% at NextPlat (NXPL), but revenue falls.
NextPlat (NXPL) reported a 21% decrease in nine-month revenue to $32.2 million for the period ending September 30, 2026, compared to the previous year. Despite the revenue decline, the company significantly narrowed its net loss by 66% to $2.024 million and improved its gross profit. Key factors influencing these results include an increase in pharmacy contract revenue and the implementation of cost reduction measures, alongside a notable adjudication suspension by Oscar Health impacting future revenue.
Clover Health Investments, Corp. News — NASDAQ:CLOV
This article provides a news feed for Clover Health Investments, Corp. (NASDAQ: CLOV), highlighting recent headlines, key facts, and analyst updates. It covers topics such as Q3 2026 earnings, guidance raises, Medicare rating gains, AI care initiatives, and price target adjustments from various financial news sources. The news indicates a focus on membership growth, profitability, and strategic partnerships.
CAH: Cardinal Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Cardinal Health Inc. filed an SEC Form 8-K reporting the results of its annual meeting held on November 12, 2026. Shareholders re-elected all 11 directors, approved executive compensation on a non-binding basis, and ratified Ernst & Young LLP as the independent auditor for fiscal year 2027. The votes were largely one-sided, indicating broad shareholder satisfaction with the board and management.
Florida fines 13 pharmacy benefit managers $12.66 million, including a CVS-affiliated company
Florida has levied $12.66 million in fines against 13 pharmacy benefit managers (PBMs), including a CVS Health company, for violating state laws related to fair pricing, network adequacy, and pharmacy contracts. These penalties are the result of market conduct examinations under Florida's Prescription Drug Reform Act, with several companies contesting the findings. Regulators are pressing for greater transparency and accountability from PBMs, warning of further enforcement for non-cooperation.
Is Cigna Group (CI) Below Fair Value On Mixed Q3 2026 Earnings?
Cigna Group (CI) released mixed Q3 2026 earnings, reporting higher sales and revenue but lower net income and EPS. Despite recent share gains, the stock trades below analyst targets and appears significantly undervalued, with a narrative fair value estimate of $636.28 against its closing price of $297.00. The perceived undervaluation is attributed to market concerns regarding political hostility towards PBMs, regulatory monitoring of Express Scripts, and other operational uncertainties, reducing the actionable margin of safety.
CVS Health study highlights GLP-1 benefits and the affordability challenge
CVS Health released a study using Aetna claims data that found GLP-1 users had better clinical outcomes and lower medical spending, but these savings did not offset the high drug costs at current prices. The research suggests a break-even net price of approximately $350 per month over three years is needed for broader sustainable access. The study identifies price and patient selection as key barriers to wider GLP-1 adoption, indicating that lower prices are essential to close the affordability gap.
CVS Health study highlights GLP-1 benefits and the affordability challenge
A CVS Health study utilizing Aetna claims data indicates that GLP-1 users experience better clinical outcomes and lower medical spending compared to non-users. However, the current medical savings do not fully offset the high cost of the drugs, with a modeled break-even net price estimated at $350 per month over three years. The research identifies price and patient selection as key barriers to wider GLP-1 access, suggesting that lower prices are necessary for broader sustainable access.
3 Health Insurance Stocks Facing Pressure From GLP 1 Weight Loss Drug Prices
The article discusses how the rising costs of GLP-1 weight loss drugs are impacting health insurance companies, with CVS Health suggesting prices need to drop significantly to be affordable. It highlights three health insurers—Humana (HUM), Molina Healthcare (MOH), and Centene (CNC)—that are particularly exposed to these pricing pressures due to their reliance on Medicare Advantage and government-backed managed care programs. The piece explores how these drug costs could reshape their long-term margin profiles and earnings paths.